The European Innovation Council (EIC), in collaboration with EuroQuity-Bpifrance, is bringing you a new opportunity to discover some of the most groundbreaking EIC-backed healthcare technologies. Sign up for the EIC & EuroQuity-Bpifrance Healthcare Investor Day, on 23 October, and seize your chance to join pitching sessions, engage innovators in one-to-one meetings and find new investment opportunities.
Did you know that 4 out of the 11 EIC-backed unicorns come from the healthcare vertical? These are only some of the many success stories from the EIC’s strong portfolio of health innovators, which are developing groundbreaking solutions to tackle the challenges in the sector.
As an investor, you will have the chance to get to know a select list of these quality-stamped companies in an upcoming event organized in partnership with EuroQuity-Bpifrance on 23 October, at the Bpifrance building on 6-8 bd Haussmann, 75009 Paris.
This event is free of charge, but the places are limited, so make sure you register before 15 October to reserve your spot.
Who can join?
The EIC is looking for qualified investors active in the healthcare field, such as Venture Capitalists, Corporate VCs, Family Offices, Angel Investors, etc.
Don’t forget to sign up for the EIC Co-Investment Platform to make the most of the event and find exciting new opportunities.
Which companies will participate?
The EIC portfolio features innovators working on medtech, new therapeutics, pharma, neurotech and diagnosis, among many other healthcare areas.
The final list of pitching companies was selected by a panel of top-level jury members, including investors from 50Partners, Adbio Partners, Agelini Ventures, Cap Horn, Debiopharm, Dieter von Holtzbrinck Ventures, Earlybird Venture Capital, EIT Health, Elaia Partners, FASE - Financing Agency for Social Entrepreneurship, HTGF, HV Capital, Invivo Capital, Karista, Karot Capital, Kurma Partners, LifeX Ventures, Miura Health Capital, Novartis, Omnes Capital, Panakès Partners, Seroba Life Sciences, Speedinvest, Sofinnova Partners, Supernova Invest, Truffle Capital, Verge HealhTech Fund, Vesalius Biocapital, Verve Ventures.
You can find the full list of pitching companies below:
Session 1 – Biotech and Pharmaceuticals
Actome GmbH
Actome is a biotech start-up developing cutting-edge technology in the field of proteomics and interactomics. They are based in Freiburg, Germany, a thriving pharmaceutical and biotechnological hub in Europe. Their business is based on a novel molecular biological analysis technology termed Protein Interaction Coupling (PICO), invented by one of the founders Dr. Csaba Jeney.
They are on a Incubator/Accelerator funding round, raising €8 million.
Celeris Therapeutics
Celeris Therapeutics - the pioneering in AI-driven proximity-inducing compound development. They design novel proximity-inducing compounds (PICs™) to treat diseases with high unmet medical need. Their patent-filed approach uses active machine learning to predict biomolecular interactions and generate new chemical entities. The wholly-owned pipeline is focused on degrader development in oncology and CNS disorders, while the company is open to partnerships across all indication areas.
They are on a Seed funding round, raising €5 million.
iLoF
iLoF is a digital health company pioneering a breakthrough Al-platform to accelerate the future of personalized drug discovery and development. Through advanced Al and Photonics, it is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, and has been regularly featured by outlets like Tech Crunch, Wired, or Sifted as a rising star in Al-Driven Drug Discovery, Health Screening & Data Analytics.
They are on a Seed funding round, raising €10 million.
IMMUNETHEP
IMMUNETHEP is a Biotech that has developed a breakthrough vaccine (PNV - Paragon Novel Vaccine) that will effectively protect against multiple bacterial infections from the main bacteria responsible for the increasing Antimicrobial Resistance (AMR). PNV will become the world’s 1st vaccine to prevent all serotypes of multiple bacterial infections, including multi-resistant strains.
They are on a Series A funding round, raising €7.5 million.
PROSION Therapeutics
A radically new therapeutic approach that aims to improve the quality of life of cancer patients and beyond: PROSION Therapeutics is a biotech & drug development company with a proprietary LEGO-like platform, aiming to address highly unmet medical needs by unlocking undruggable protein targets.
They are on a Series A funding round, raising €13-15 million.
TILT Biotherapeutics
TILT Biotherapeutics is a privately owned clinical-stage biotechnology company developing cancer immunotherapies based on its proprietary oncolytic viruses. The company’s patented TILT® technology, which can be delivered systemically and locally, is in clinical development for ovarian cancer, head & neck cancer, melanoma, and lung cancer. With operations in Europe and the U.S., the company drives forward its lead program, igrelimogene litadenorepvec (TILT-123), towards Phase 2 development in ovarian cancer. TILT is interested in partnering with companies with synergic products such as ICIs and T-cell therapies and with strong capabilities for later stage clinical development.
They are on a Series B funding round, raising €50 million.
NETRIS Pharma
NETRIS Pharma is a clinical stage (phase2) and world most advanced biotech targeting NETRIN-1 to alleviate resistance to immunotherapy and chemotherapy in oncology. 4 clinical trials are currently enrolling 400+ patients. The mode of action of its lead asset NP137 (monoclonal antibody) has been published in august 2023 in 2 papers in Nature(R).
They are on a Series A funding round, raising €2 million.
Session 2 – E-Health
FEops NV
FEops is providing physicians with a unique digital platform, FEops HEARTguide, to treat the right heart disease patients with the right technology at the right time.
They are on a Series A funding round, raising €7 million.
SquareMind
SquareMind develops a next-generation skin cancer screening solution, to augment physicians with breakthrough imaging and AI and boost the revenues of centres.
They are on a Series A funding round.
Yonalink
Yonalink collects clinical trial participants data from medical centers EMR and transfers it to clinical trial sponsors database in real-time by using streaming technologies and AI-driven data mapping that puts patient data directly in the right place in the sponsor’s EDC (electronic data capture). The result is improved prospective clinical trial efficiency and data quality, reduced medical center staff burnout, and greater data oversight. With a global network of over 7,000 medical centers, sponsors and CROs can leverage Yonalink to increase patient diversity, and medical centers can attract new trials and provide patients with wider access to novel, lifesaving therapies.
They are on a Series A funding round, raising €15 million.
GrayMatters Health
GrayMatters develops self-neuromodulation therapies for mental disorders using a proprietary technology fusing EEG and fMRI data to produce brain biomarkers. Prism for PTSD, the first product using its amygdala-derived-biomarker, received FDA clearance as a prescribed adjunct therapy for PTSD. Pipeline includes Depression,ADHD, and other disorders.
They are on a Series B funding round, raising $20+ million.
INBRAIN Neuroelectronics
INBRAIN Neuroelectronics is a new platform company at the intersection of Medtech, Deeptech and Digital Health dedicated to the development of neuroelectronic therapies through graphene-based high-resolution intelligent neural interfaces, with unprecedented stimulation and recording capabilities for the treatment of neurological-based disorders.
They are on a Series A funding round, raising €10-15 million.
MethinksAI
Methinks AI’s vision is to provide universal and timely diagnosis for life-saving treatments worldwide. Their first focus is on stroke, the major cause of disability and second cause of death. Their CE Mark product is the first AI capable of reducing time-to-treatment up to 60 minutes. In stroke, “time is brain”. Every minute increases risks of disability or death.
They are on a Series A funding round, raising €15 million.
Session 3 – MedTech
Capri Medical
Capri Medical develops injectable neurostimulation devices.
They are on a Series A funding round, raising €7 million.
CorWave
CorWave is a deeptech industrial startup that develops and manufactures innovative mechanical circulatory support medical devices for heart failure patients.
They are on a Series A funding round, raising €7 million.
Glycanostics s.r.o.
Glycanostics has developed highly accurate, early-stage tests for detection of 11 types of cancer based on analysis of glycans in blood. The tests are highly affordable, suitable for massive screening, organ specific and compatible with equipment already used by laboratories world-wide (ELISA).
They are on a Series A funding round, raising €5 million.
InVera Medical
InVera is a clinical-stage medical device company that offers a less-invasive pure mechanical endovascular ablation treatment of varicosity and venous ulcer symptoms without pain, burning, or permanent implants.
They are on a Series A funding round, raising €20 million.
ORIXHA
ORIXHA is a DeepTech company that develops and commercializes medical devices based on a unique and patented "Lung Conservative Liquid Ventilation" technology referred to under the acronym LuncoLive. Total liquid ventilation (TLV) by Luncolive is an extracorporeal circulation of a breathable liquid that ventilates the lungs and provides respiratory support to intubated and comatose patients. The medical devices under development at Orixha will save the lives of critical care patients.
They are on a Series A funding round, raising €11 million.
Tucuvi
Tucuvi is a HealthTech company that helps healthcare organizations to automate outpatient communication using state-of-the-art voice conversational AI. On a mission to boost healthcare systems efficiency, we offer a clinically validated and customizable CE-marked SaMD solution and care processes designed to deliver real value to patients.
They are on a Seed funding round, raising €6 million.
Neuroclues
NeuroClues is a MedTech startup aiming to become the brain’s stethoscope. Their platform leverages eye-tracking technology to provide non-invasive, simple, and robust biomarkers to detect cognitive and neurological disorders, like Parkinson's Disease, 10x faster than current methodologies.
They are on a Seed funding round, raising €14 million.
About EuroQuity-Bpifrance
Operated by Bpifrance (the French Public Investment Bank), EuroQuity is a matchmaking platform dedicated to economic development and an essential source of financing for SMEs. Its mission is to accelerate the growth of companies throughout Europe and beyond by giving concrete credentials to companies to maximize their opportunities to meet and match with investors, through their membership in e-communities and e-labels.
The EIC and EuroQuity-Bpifrance have previously teamed up to deliver a number of successful ePitchings and Investor Days.
About the EIC Ecosystem Partnerships and Co-Investment Support Programme
The Ecosystem Partnerships and Co-Investment Support Programme is expanding the EIC’s Business Acceleration Services (BAS) by creating a network of specialized, sector-focused partners that can help innovators access the services they need. It is also dedicated to promoting co-investment along with the EIC Fund, by preparing beneficiaries to interact with investors and connecting them through matchmaking and dedicated events.
Should you have any questions regarding the event, please contact us through the email events@eicfund.eu.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.